补体基因变异与产志贺毒素大肠杆菌相关溶血性尿毒症综合征:回顾性遗传与临床研究
该回顾性研究对108例临床诊断为腹泻后HUS的儿童(75例志贺毒素阳性,33例阴性)及80名法国对照进行补体生物标志物检测和6个非典型HUS易感基因二代测序,并分析503名欧洲个体基因型作为独立对照。结果显示急性期C3和sC5b-9升高,半数患者膜辅因子蛋白表达下降;仅MAF<0.1%的致病性变异在志贺毒素阳性HUS中更常见(4% vs 0.8%,OR 5.2,95%CI 1.1-24,P=0.03),但遗传背景未显著影响透析需求、神经系统表现、sC5b-9水平及随访CKD发生。
要点
- 志贺毒素阳性HUS患儿中MAF<0.1%的补体基因致病性变异频率高于欧洲对照(4% vs 0.8%)。
- 罕见变异及补体激活生物标志物与HUS严重程度无显著关联。
- 唯一3年内进展至ESKD的患儿携带补体因子H致病性变异。
核心结论
- 罕见补体基因变异和补体激活生物标志物与产志贺毒素大肠杆菌相关HUS的严重程度无关。
- 仅MAF<0.1%的致病性变异在志贺毒素阳性HUS患者中比对照更常见。
研究设计与样本
- 回顾性遗传与临床研究,纳入108例临床诊断为腹泻后HUS的儿童(75例志贺毒素阳性,33例阴性)和80名法国对照。
- 对6个非典型HUS易感基因进行二代测序,检测补体生物标志物水平。
- 另分析503名欧洲个体(1000基因组计划)基因型作为独立对照。
主要发现
- 急性期HUS患者血浆C3和sC5b-9水平升高,半数患者膜辅因子蛋白表达下降,2周后恢复正常。
- 12例志贺毒素阳性HUS患者(16%)检出MAF<1%的变异,其中4例(5%)为致病性变异,与志贺毒素阴性HUS和对照无显著差异。
- 3例志贺毒素阳性HUS患者(4%)检出MAF<0.1%的致病性变异,欧洲对照仅4例(0.8%)(OR 5.2;95%CI 1.1-24;P=0.03)。
- 遗传背景对急性期透析需求、神经系统表现、sC5b-9水平及随访期间新发CKD无显著影响。
- 唯一3年内进展至ESKD的患者携带补体因子H致病性变异。
关键数值与推荐
- MAF<0.1%的致病性变异在志贺毒素阳性HUS中频率为4%(3/75),欧洲对照为0.8%(4/503),OR 5.2(95%CI 1.1-24),P=0.03。
- MAF<1%的变异在志贺毒素阳性HUS中检出率为16%(12/75),致病性变异为5%(4/75)。
临床怎么用
- 对志贺毒素相关HUS患儿可考虑补体基因检测,尤其关注MAF<0.1%的致病性变异。
- 补体生物标志物和罕见变异暂不能用于预测HUS急性期严重程度或长期肾脏预后。
- 携带补体因子H致病性变异的患儿可能需更密切随访肾功能。
局限性
- 回顾性研究设计,样本量有限(108例患儿)。
- 对照群体为法国及欧洲人群,可能存在人群分层差异。
- 未报告变异功能验证及长期随访的详细数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Inherited complement hyperactivation is critical for the pathogenesis of atypical hemolytic uremic syndrome (HUS) but undetermined in postdiarrheal HUS. Our aim was to investigate complement activation and variants of complement genes, and their association with disease severity in children with Shiga toxin-associated HUS. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Determination of complement biomarkers levels and next-generation sequencing for the six susceptibility genes for atypical HUS were performed in 108 children with a clinical diagnosis of post-diarrheal HUS (75 Shiga toxin-positive, and 33 Shiga toxin-negative) and 80 French controls. As an independent control cohort, we analyzed the genotypes in 503 European individuals from the 1000 Genomes Project. RESULTS: During the acute phase of HUS, plasma levels of C3 and sC5b-9 were increased, and half of patients had decreased membrane cofactor protein expression, which normalized after 2 weeks. Variants with minor allele frequency <1% were identified in 12 Shiga toxin-positive patients with HUS (12 out of 75, 16%), including pathogenic variants in four (four out of 75, 5%), with no significant differences compared with Shiga toxin-negative patients with HUS and controls. Pathogenic variants with minor allele frequency <0.1% were found in three Shiga toxin-positive patients with HUS (three out of 75, 4%) versus only four European controls (four out of 503, 0.8%) (odds ratio, 5.2; 95% confidence interval, 1.1 to 24; P=0.03). The genetic background did not significantly affect dialysis requirement, neurologic manifestations, and sC5b-9 level during the acute phase, and incident CKD during follow-up. However, the only patient who progressed to ESKD within 3 years carried a factor H pathogenic variant. CONCLUSIONS: Rare variants and complement activation biomarkers were not associated with severity of Shiga toxin-associated HUS. Only pathogenic variants with minor allele frequency <0.1% are more frequent in Shiga toxin-positive patients with HUS than in controls.
引用
- Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, et al. Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. Clin J Am Soc Nephrol. 2019. PMID: 30674459. doi:10.2215/CJN.05830518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。